Mercer Global Advisors
JAZZ icon

Mercer Global Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Mercer Global Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.09M Buy
21,124
+10,007
+90% +$2.19M 0.01% 866
2026
Q1 		$2.1M Buy
11,117
+4,170
+60% +$729K ﹤0.01% 1179
2025
Q4 		$1.18M Buy
6,947
+4,467
+180% +$685K ﹤0.01% 1368
2025
Q3 		$327K Sell
2,480
-564
-19% -$67.6K ﹤0.01% 2027
2025
Q2 		$323K Buy
3,044
+1,332
+78% +$145K ﹤0.01% 1813
2025
Q1 		$213K Buy
1,712
+71
+4% +$9.26K ﹤0.01% 1938
2024
Q4 		$202K Sell
1,641
-1,686
-51% -$199K ﹤0.01% 1968
2024
Q3 		$371K Sell
3,327
-158
-5% -$17.3K ﹤0.01% 1514
2024
Q2 		$372K Buy
3,485
+1,187
+52% +$131K ﹤0.01% 1470
2024
Q1 		$277K Sell
2,298
-365
-14% -$44.7K ﹤0.01% 1609
2023
Q4 		$328K Sell
2,663
-112
-4% -$14K ﹤0.01% 1554
2023
Q3 		$359K Buy
2,775
+79
+3% +$10.5K ﹤0.01% 1418
2023
Q2 		$334K Sell
2,696
-632
-19% -$85K ﹤0.01% 1452
2023
Q1 		$487K Sell
3,328
-625
-16% -$92.4K ﹤0.01% 1219
2022
Q4 		$630K Sell
3,953
-111
-3% -$16.3K ﹤0.01% 1101
2022
Q3 		$542K Sell
4,064
-505
-11% -$76.8K ﹤0.01% 1096
2022
Q2 		$713K Sell
4,569
-257
-5% -$39.6K ﹤0.01% 984
2022
Q1 		$751K Sell
4,826
-1,722
-26% -$250K ﹤0.01% 1027
2021
Q4 		$834K Sell
6,548
-599
-8% -$78.7K 0.01% 969
2021
Q3 		$931K Sell
7,147
-4,114
-37% -$622K 0.01% 887
2021
Q2 		$2M Sell
11,261
-515
-4% -$89.2K 0.02% 571
2021
Q1 		$1.94M Sell
11,776
-617
-5% -$102K 0.02% 530
2020
Q4 		$2.04M Sell
12,393
-24,223
-66% -$3.61M 0.03% 414
2020
Q3 		$5.22M Sell
36,616
-163
-0.4% -$20.2K 0.08% 192
2020
Q2 		$4.06M Buy
36,779
+8,779
+31% +$971K 0.07% 194
2020
Q1 		$2.79M Buy
28,000
+24,919
+809% +$3.22M 0.06% 252
2019
Q4 		$460K Buy
3,081
+336
+12% +$45.7K 0.01% 760
2019
Q3 		$351K Sell
2,745
-82
-3% -$11K 0.01% 837
2019
Q2 		$403K Buy
2,827
+258
+10% +$34.7K 0.01% 760
2019
Q1 		$367K Buy
+2,569
New +$335K 0.01% 749

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Mercer Global Advisors's JAZZ Position: Q2 2026 in Review

Mercer Global Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 90% in Q2 2026, buying an estimated $2.19M and bringing the position to 21,124 shares worth $5.09M. The position accounts for 0.01% of the portfolio, ranked #866.

Mercer Global Advisors first reported a position in JAZZ in Q1 2019 and has held it in 30 quarters since. The position peaked at $5.22M in Q3 2020. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Mercer Global Advisors held 21,124 shares of Jazz Pharmaceuticals worth $5.09M as of Q2 2026.
  • Mercer Global Advisors bought 10,007 Jazz Pharmaceuticals shares in Q2 2026, an estimated $2.19M.
  • Jazz Pharmaceuticals made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #866 holding.
  • Mercer Global Advisors first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
  • Mercer Global Advisors's Jazz Pharmaceuticals position peaked at $5.22M in Q3 2020.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.